001     852453
005     20210129235057.0
024 7 _ |a 10.1016/j.neuropharm.2017.04.011
|2 doi
024 7 _ |a 0028-3908
|2 ISSN
024 7 _ |a 1873-7064
|2 ISSN
024 7 _ |a pmid:28400256
|2 pmid
024 7 _ |a WOS:000403513800010
|2 WOS
024 7 _ |a altmetric:18791709
|2 altmetric
037 _ _ |a FZJ-2018-05399
082 _ _ |a 610
100 1 _ |a Sergeeva, Olga A.
|0 P:(DE-HGF)0
|b 0
|e Corresponding author
245 _ _ |a N-oleoyldopamine modulates activity of midbrain dopaminergic neurons through multiple mechanisms
260 _ _ |a Amsterdam [u.a.]
|c 2017
|b Elsevier Science
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1539670400_30352
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a N-oleoyl-dopamine (OLDA) is an amide of dopamine and oleic acid, synthesized in catecholaminergic neurons. The present study investigates OLDA targets in midbrain dopaminergic (DA) neurons. Substantia Nigra compacta (SNc) DA neurons recorded in brain slices were excited by OLDA in wild type mice. In transient receptor potential vanilloid 1 (TRPV1) knockout (KO) mice, however, SNc DA neurons displayed sustained inhibition of firing. In the presence of the dopamine type 2 receptor (D2R) antagonist sulpiride or the dopamine transporter blocker nomifensine no such inhibition was observed. Under sulpiride OLDA slightly excited SNc DA neurons, an action abolished upon combined application of the cannabinoid1 and 2 receptor antagonists AM251 and AM630. In ventral tegmental area (VTA) DA neurons from TRPV1 KO mice a transient inhibition of firing by OLDA was observed. Thus OLDA modulates the firing of nigrostriatal DA neurons through interactions with TRPV1, cannabinoid receptors and dopamine uptake. These findings suggest further development of OLDA-like tandem molecules for the treatment of movement disorders including Parkinson's disease.
536 _ _ |a 573 - Neuroimaging (POF3-573)
|0 G:(DE-HGF)POF3-573
|c POF3-573
|f POF III
|x 0
536 _ _ |a 571 - Connectivity and Activity (POF3-571)
|0 G:(DE-HGF)POF3-571
|c POF3-571
|f POF III
|x 1
588 _ _ |a Dataset connected to CrossRef
700 1 _ |a De Luca, Roberto
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Mazur, Karolina
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Chepkova, Aissa N.
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Haas, Helmut L.
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Bauer, Andreas
|0 P:(DE-Juel1)131672
|b 5
773 _ _ |a 10.1016/j.neuropharm.2017.04.011
|g Vol. 119, p. 111 - 122
|0 PERI:(DE-600)1500655-4
|p 111 - 122
|t Neuropharmacology
|v 119
|y 2017
|x 0028-3908
856 4 _ |u https://juser.fz-juelich.de/record/852453/files/N-oleoyldopamine%20modulates%20activity%20of%20midbrain%20dopaminergic%20neurons%20through%20multiple%20mechanisms.pdf
|y Restricted
856 4 _ |u https://juser.fz-juelich.de/record/852453/files/N-oleoyldopamine%20modulates%20activity%20of%20midbrain%20dopaminergic%20neurons%20through%20multiple%20mechanisms.pdf?subformat=pdfa
|x pdfa
|y Restricted
909 C O |o oai:juser.fz-juelich.de:852453
|p VDB
910 1 _ |a Medical Faculty of Heinrich-Heine University
|0 I:(DE-HGF)0
|b 0
|6 P:(DE-HGF)0
910 1 _ |a Medical Faculty of Heinrich-Heine University
|0 I:(DE-HGF)0
|b 1
|6 P:(DE-HGF)0
910 1 _ |a Medical Faculty of Heinrich-Heine University
|0 I:(DE-HGF)0
|b 2
|6 P:(DE-HGF)0
910 1 _ |a Medical Faculty of Heinrich-Heine University
|0 I:(DE-HGF)0
|b 3
|6 P:(DE-HGF)0
910 1 _ |a Medical Faculty of Heinrich-Heine University
|0 I:(DE-HGF)0
|b 4
|6 P:(DE-HGF)0
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 5
|6 P:(DE-Juel1)131672
910 1 _ |a Medical Faculty of Heinrich-Heine University
|0 I:(DE-HGF)0
|b 5
|6 P:(DE-Juel1)131672
913 1 _ |a DE-HGF
|b Key Technologies
|l Decoding the Human Brain
|1 G:(DE-HGF)POF3-570
|0 G:(DE-HGF)POF3-573
|2 G:(DE-HGF)POF3-500
|v Neuroimaging
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
913 1 _ |a DE-HGF
|b Key Technologies
|l Decoding the Human Brain
|1 G:(DE-HGF)POF3-570
|0 G:(DE-HGF)POF3-571
|2 G:(DE-HGF)POF3-500
|v Connectivity and Activity
|x 1
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
914 1 _ |y 2018
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NEUROPHARMACOLOGY : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
920 _ _ |l yes
920 1 _ |0 I:(DE-Juel1)INM-2-20090406
|k INM-2
|l Molekulare Organisation des Gehirns
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-Juel1)INM-2-20090406
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21